Shape Therapeutics is developing RNA technologies to shape the future of gene therapies. To achieve this, Shape has built their gene therapy platform, comprising RNAskip, RNAfix and RNAswap payload technologies and tissue-specific AAVid delivery technology. Data output from the platform is then incorporated into Shape’s AI engine, where data drives decisions to select the next gene therapies that are scalable and curative for many diseases. This combination of cutting-edge science and drug development expertise is enabling Shape to advance breakthroughs in RNA editing to correct mutations, fine-tune gene expression and modulate protein interactions. Currently, Shape is focusing on therapies for Parkinson’s disease and the ocular disorder Stargardt disease.